Antibody responses to four Haemophilus influenzae type b conjugate vaccines

Am J Dis Child. 1991 Feb;145(2):223-7. doi: 10.1001/archpedi.1991.02160020117030.

Abstract

Serum antibody responses to four Haemophilus influenzae type b capsular polysaccharide-protein conjugate vaccines (PRP-D, HbOC, C7p, and PRP-T) were studied and compared in 175 infants, 85 adults and 140 2-year-old children. Antibodies to the H influenzae type b polysaccharide vaccines were determined with a Farr-type radioimmunoassay. The infants received two doses of vaccine at the ages of 4 and 6 months. After the first dose of vaccine, the geometric mean antibody concentration measured at the age of 6 months was 0.09 to 0.10 mg/L, only marginally higher than that measured before immunization in all infants who had received PRP-D, HbOC, or C7p but increased to 0.82 mg/L in those who had received PRP-T. One month after the second dose, the geometric mean antibody concentration was increased in all vaccine groups. No significant differences were noted between recipients of HbOC, C7p, or PRP-T (geometric mean antibody concentrations, 4.32, 3.10, and 6.10 mg/L, respectively), whereas the PRP-D recipients had a significantly lower geometric mean antibody concentration (0.63 mg/L). In contrast, PRP-D, HbOC, C7p, and PRP-T were all highly immunogenic in adults, with no differences noted among them. The 2-year-old children also responded to one dose of these vaccines with a high antibody concentration.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Bacterial / blood*
  • Bacterial Proteins
  • Bacterial Vaccines / adverse effects
  • Bacterial Vaccines / immunology*
  • Child, Preschool
  • Diphtheria Toxoid
  • Female
  • Haemophilus Infections / prevention & control
  • Haemophilus Vaccines*
  • Haemophilus influenzae / immunology*
  • Humans
  • Infant
  • Male

Substances

  • Antibodies, Bacterial
  • Bacterial Proteins
  • Bacterial Vaccines
  • Diphtheria Toxoid
  • Haemophilus Vaccines
  • Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate
  • HibTITER protein, Haemophilus influenzae